A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price
The FDA risks being pulled into an ugly political fracas over whether to permit more patients to be treated with hydroxychloroquine.
Read The StoryPolitics
Tracking how politics and policy influence health care and medicine. To get the latest delivered to your inbox, sign up for our free D.C. Diagnosis newsletter. And subscribe to STAT Plus for inside intelligence on the intersection of Capitol Hill and the life sciences.
What does the FDA’s hydroxychloroquine decision mean for Covid-19 patients or politicians? And 4 other burning questions
AAMC, the medical school trade association, gave $500,000 to dark-money group in 2018
Pharma is showering Congress with cash, even as drug makers race to fight the coronavirus
‘A number of new stars’: The definitive guide to the Trump administration’s coronavirus response team
All Coverage
advertisement
